Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Planning of scanning during adjuvant nivolumab for esophageal cancer
NL-OMON57882Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in esophageal cancer and esophagogastric junction cancer, sponsored by Erasmus MC. Primary endpoint: Proportion of patients with locoregional and/or distant metastasis. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON57882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57882.